For personal use only

ALGORAE PHARMACEUTICALS

ASX ANNOUNCEMENT

ASX: 1AI | 16 October 2026

Algorae Pharmaceuticals Partners with Peter MacCallum Cancer Centre for Third AI-driven Drug Synergy Screening Program

Highlights

- Algorae Pharmaceuticals has entered into an agreement with the Victorian Centre for Functional Genomics (VCFG) at Peter MacCallum Cancer Centre for a third program to independently validate predictions generated by the AlgoraeOS v2 (AOS2) multi-anchor program.
- Forty high-priority drug combination candidates will be screened for synergy across four cancer cell lines representing glioblastoma, non-small cell lung cancer, colorectal cancer and bladder cancer.
- Candidate combinations were selected for validation from the multi-anchor program (announced 18 May 2026) which evaluated 18 anchor drugs in combination with thousands of approved and investigational compounds.
- This program is supported by a Therapeutic Innovation Australia Pipeline Accelerator voucher of $49,109 awarded to the Company to support experimental work in partnership with the VCFG.
- The project is expected to be completed within six months.

AI-enabled pharmaceutical company **Algorae Pharmaceuticals Ltd (ASX: 1AI)** has entered into an agreement with the **Victorian Centre for Functional Genomics** ("VCFG") at **Peter MacCallum Cancer Centre** ("Peter Mac") for a third program to independently validate the predictions from the AOS2 multi-anchor program.

As announced on 18 May 2026, Algorae completed a preliminary examination of the AOS2 prediction set which evaluated 18 anchor drugs in combination with thousands of approved and investigational compounds across a panel of human cell lines, representing over **9 million potential drug–drug–cell line combinations**. The 18 anchors were selected to span a diverse range of therapeutic areas and mechanisms of action. Following analysis of commercial and intellectual property considerations, **40 high-priority drug combination candidates** have been selected for preclinical validation. The combinations selected use a subset of the anchors chosen for the *in silico* analysis.

Under the agreement, VCFG will perform compound synergy interaction screens using its high-throughput technologies and synergy assessment methodologies. The collaboration is designed to evaluate the predicted synergy of drug combinations across four distinct cancer cell lines: glioblastoma, non-small cell lung cancer, colorectal cancer and bladder cancer.

For personal use only

Commenting on the collaboration, Algorae Chief Scientific Officer, **Dr James McKenna** said:

"This study builds on the foundations established through our previous two collaborations with the VCFG team at the Peter MacCallum Cancer Centre. It represents another important step in the development of AOS2, allowing us to assess the real-world generalisability of the platform across multiple anchor drugs. Importantly, the study also provides a further demonstration of how AOS can help bridge the gap between in silico prediction and biological validation."

AOS2 multi-anchor program

The multi-anchor prediction set evaluated 18 anchor drugs in combination with thousands of approved and investigational compounds across a panel of human cell lines. Each prediction in the dataset included the four well-recognised synergy metrics (**ZIP, Bliss, HSA and Loewe**) alongside confidence-weighted measures of predictive uncertainty. Prioritisation thresholds were informed by, and refined from, the methodology successfully applied to the previous AOS2 prediction set. These thresholds balance the magnitude of predicted synergy with uncertainty reduction and biological generalisability across multiple cell lines.

In summary:

AOS2 evaluated over **9 million potential drug–drug–cell line combinations** across the 18 anchor drugs. From this prediction set, initial filtering identified:

- more than **478,000 individual synergy predictions** passing preliminary synergy and uncertainty thresholds;
- over **6,000 drug combinations** demonstrating predicted synergy across multiple cell lines, indicating greater biological robustness.

To further prioritise candidates for empirical validation, anchor-specific considerations and additional filters were then applied, reflecting the predicted strength of synergy, biological generalisability, and commercial and intellectual property relevance.

This program is supported by a competitive voucher of $49,109 awarded to the Company under the Phenomics Australia – Therapeutic Innovation Australia Pipeline Accelerator 2025-26 Round 2 scheme, to support experimental work in partnership with the VCFG.

The scheme attracted 28 applications, of which 13 were selected for funding, and the award reduces the total cost to the Company of accessing these services.

Empirical validation and timeline

The program will investigate 40 drug combinations selected from the multi-anchor prediction set. Only a subset of the 18 investigated anchors has been progressed.

The screening process, to be performed by VCFG at Peter Mac using its high-throughput microscopy platform, will include:

- Cell growth optimisation for the high-throughput platform.
- Single-agent dose-response curves across four cancer cell lines.
- Synergy screens using selected dose ranges.

For personal use only

Data analysis will be completed within three weeks of the synergy screen, with the full dataset expected within six months. Key decision points will be integrated into the study to ensure data quality and optimise further testing.

Implications and next steps

This work builds on the independent preclinical validation of AlgoraeOS v1 (AOS1) at Peter Mac (refer ASX announcement dated 5 December 2025) and AOS2 (refer ASX announcement dated 3 July 2026).

Promising candidates identified from the current program and the previous two programs will inform the Company's ongoing discussions with Peter Mac. Priority candidates from the initial two programs have been shortlisted, and discussions are under way to advance their development through a combination of in vitro assays and in vivo animal models.

In parallel with the Company's AI drug discovery activities, the commercial pharmaceutical business continues to advance, with additional products and agreements progressing through the pipeline. Algorae will continue to update shareholders as key commercial and scientific milestones are achieved.

About Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world-leading cancer research, education and treatment centre and Australia's only public health service solely dedicated to caring for people affected by cancer. The Victorian Centre for Functional Genomics was established over 16 years ago and is an internationally recognised technology platform (co-supported by Phenomics Australia, a National Collaborative Research Infrastructure Strategy consortium) that enables advanced high throughput screens using gene and drug targeting strategies coupled with innovative image analytics.

Peter Mac currently treats more than 47,000 patients every year, combining care and compassion with the latest research to deliver the best possible treatments, care and outcomes for patients. This care is matched with world-class facilities within the Parkville Biomedical Precinct and at six additional metropolitan and regional campuses.

https://www.petermac.org

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: investors@algoraepharma.com

ALGORAE PHARMACEUTICALS

For personal use only

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.